A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases

• Published in: Nature communications Vol. 13; no. 1; pp. 6602 - 11
• Main Authors: Yasuhara, Atsuhiro, Yamayoshi, Seiya, Kiso, Maki, Sakai-Tagawa, Yuko, Okuda, Moe, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03.11.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 13/1; 631/250/2152/2153/1291; 631/250/255/1578; 631/326/596/1578; 64/60; Antibodies; Antibodies, Monoclonal - pharmacology; Antibodies, Viral; Antigens; Antiviral agents; Antiviral drugs; Binding; Chemical compounds; Epitopes; Exo-a-sialidase; Glycoproteins; Hemagglutinins; Herpesvirus 1, Cercopithecine; Humanities and Social Sciences; Humans; Influenza; Influenza A; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Influenza Vaccines; Influenza, Human; Monoclonal antibodies; multidisciplinary; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Pharmacology; Science; Science (multidisciplinary); Vaccine development; Vaccines; Viruses

Improved vaccines and antiviral agents that provide better, broader protection against seasonal and emerging influenza viruses are needed. The viral surface glycoprotein hemagglutinin (HA) is a primary target for the development of universal influenza vaccines and therapeutic antibodies. The other m...